AN2 Therapeutics focuses on modern biomedical and drug development expertise to provide transformational medicines.
AN2 Therapeutics has raised $40.0M in total funding. The most recent round was Post-IPO Equity. The last funding was announced in March 2026.
AN2 Therapeutics's investors include RA Capital Management, Vivo Capital, Bill & Melinda Gates Foundation, Janus Henderson Investors, TCG Crossover.
AN2 Therapeutics is headquartered in Menlo Park, United States.
AN2 Therapeutics focuses on modern biomedical and drug development expertise to provide transformational medicines.
AN2 Therapeutics is at the Post-IPO Equity stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"AN2 Therapeutics — Funding & Investors." VCBacked, March 9, 2026, https://www.vcbacked.co/company/an2-therapeutics. Accessed August 13, 2026.
VCBacked. (2026). AN2 Therapeutics — Funding & Investors. Retrieved August 13, 2026, from https://www.vcbacked.co/company/an2-therapeutics
{{cite web |title=AN2 Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/an2-therapeutics |website=VCBacked |access-date=August 13, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated